ATE313642T1 - Nukleinsäure enthaltende zusammensetzung, herstellung und verwendung - Google Patents

Nukleinsäure enthaltende zusammensetzung, herstellung und verwendung

Info

Publication number
ATE313642T1
ATE313642T1 AT96904146T AT96904146T ATE313642T1 AT E313642 T1 ATE313642 T1 AT E313642T1 AT 96904146 T AT96904146 T AT 96904146T AT 96904146 T AT96904146 T AT 96904146T AT E313642 T1 ATE313642 T1 AT E313642T1
Authority
AT
Austria
Prior art keywords
nucleic acid
production
composition containing
containing nucleic
vivo
Prior art date
Application number
AT96904146T
Other languages
English (en)
Inventor
Gerardo Byk
Daniel Scherman
Bertrand Schwartz
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9476267&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE313642(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE313642T1 publication Critical patent/ATE313642T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96904146T 1995-02-17 1996-02-15 Nukleinsäure enthaltende zusammensetzung, herstellung und verwendung ATE313642T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9501865A FR2730637B1 (fr) 1995-02-17 1995-02-17 Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
PCT/FR1996/000248 WO1996025508A1 (fr) 1995-02-17 1996-02-15 Compositions contenant des acides nucleiques, preparation et utilisation

Publications (1)

Publication Number Publication Date
ATE313642T1 true ATE313642T1 (de) 2006-01-15

Family

ID=9476267

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96904146T ATE313642T1 (de) 1995-02-17 1996-02-15 Nukleinsäure enthaltende zusammensetzung, herstellung und verwendung

Country Status (18)

Country Link
US (2) US5945400A (de)
EP (1) EP0809705B1 (de)
JP (1) JPH11500431A (de)
KR (1) KR19980702200A (de)
AT (1) ATE313642T1 (de)
AU (1) AU706643B2 (de)
BR (1) BR9607383A (de)
CA (1) CA2211162A1 (de)
CZ (1) CZ293269B6 (de)
DE (1) DE69635609T2 (de)
FI (1) FI973363A (de)
FR (1) FR2730637B1 (de)
HU (1) HU223263B1 (de)
IL (1) IL117144A0 (de)
NO (1) NO973745L (de)
SK (1) SK281543B6 (de)
WO (1) WO1996025508A1 (de)
ZA (1) ZA961255B (de)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5939401A (en) * 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US6331524B1 (en) 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
JP2002514892A (ja) * 1995-06-08 2002-05-21 コブラ セラピューティクス リミテッド 遺伝子治療における合成ウイルス様粒子の使用
FR2741066B1 (fr) 1995-11-14 1997-12-12 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2756491B1 (fr) * 1996-11-29 1999-01-08 Rhone Poulenc Rorer Sa Composition transfectante utile en therapie genique associan t a un virus recombinant incorporant un acide nucleique exog ene, un agent de transfection non viral et non plasmidique
FR2750704B1 (fr) 1996-07-04 1998-09-25 Rhone Poulenc Rorer Sa Procede de production d'adn therapeutique
CN1181422A (zh) * 1996-10-31 1998-05-13 上海市肿瘤研究所 与生长因子受体结合的多肽所构建的基因转移载体
KR100516561B1 (ko) 1996-12-06 2005-09-22 아벤티스 파마슈티칼스 인크. 사람 리파제-유사 유전자에 의해 암호화된 폴리펩타이드, 조성물 및 방법
US7008776B1 (en) * 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
US6884430B1 (en) 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
IL132323A0 (en) 1997-04-28 2001-03-19 Rhone Poulenc Rorer Sa Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
FR2763943B1 (fr) * 1997-05-28 1999-07-09 Rhone Poulenc Rorer Sa Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
US6875606B1 (en) 1997-10-23 2005-04-05 The United States Of America As Represented By The Department Of Veterans Affairs Human α-7 nicotinic receptor promoter
DE69927669T2 (de) 1998-01-30 2006-07-20 Aventis Pharma S.A. Für reduzierende bedingungen empfindliche transfektions-verbindungen, pharmazeutische zusammensezungen die diese enthalten und deren verwendung.
FR2774394B1 (fr) * 1998-01-30 2002-04-26 Rhone Poulenc Rorer Sa Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications
US6225456B1 (en) 1998-05-07 2001-05-01 University Technololy Corporation Ras suppressor SUR-5
US6506889B1 (en) 1998-05-19 2003-01-14 University Technology Corporation Ras suppressor SUR-8 and related compositions and methods
EP1137793A2 (de) * 1998-12-03 2001-10-04 Aventis Pharma S.A. Neue nukleinsäure-übertragungsmittel, ihre zusammensetzungen und ihre verwendungen
FR2786700B1 (fr) * 1998-12-03 2002-12-06 Aventis Pharma Sa Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs utilisations
US6441156B1 (en) * 1998-12-30 2002-08-27 The United States Of America As Represented By The Department Of Health And Human Services Calcium channel compositions and methods of use thereof
US9034329B2 (en) * 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
US7780882B2 (en) * 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
EP1154756B1 (de) * 1999-02-22 2007-01-03 Georgetown University Immunoliposome mit einem targeting-antikörperfragment zur systemischen genverabreichung
GB9918670D0 (en) 1999-08-06 1999-10-13 Celltech Therapeutics Ltd Biological product
EP1083232B1 (de) * 1999-09-09 2005-02-23 CureVac GmbH Transfer von mRNAs unter Verwendung von polykationischen Verbindungen
WO2001023537A1 (en) * 1999-09-24 2001-04-05 Cyto Pulse Sciences, Inc. Process for enhancing electric field-mediated delivery of biological materials into cells
EP1276500B1 (de) 2000-03-13 2011-06-08 Cornell Research Foundation, Inc. Blockieren der leukozytenemigration und entzündung durch störung mit cd99/hec2
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
NZ521564A (en) * 2000-04-12 2004-06-25 Implyx Ltd Compositions for drug delivery
EP1272526A4 (de) 2000-04-13 2004-10-13 Univ Rockefeller Verstärkung von antikörpervermittelten immunantworten
US20040142474A1 (en) * 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
US6696038B1 (en) * 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
FR2814370B1 (fr) * 2000-09-22 2004-08-20 Centre Nat Rech Scient Utilisation d'un complexe acide nucleique/pei pour le ciblage de cellules souches du cerveau
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
US7060442B2 (en) 2000-10-30 2006-06-13 Regents Of The University Of Michigan Modulators on Nod2 signaling
EP2402359A1 (de) 2000-12-28 2012-01-04 Wyeth LLC Rekombinantes Schutzprotein aus Streptokokkus pneumoniae
US20030125239A1 (en) * 2001-02-02 2003-07-03 Andrea Crisanti Compositions for drug delivery
WO2002063026A1 (en) * 2001-02-08 2002-08-15 Geneporter, Inc. Complexes and components thereof for introducing polynucleotides into eukaryotic cells
MXPA03007493A (es) 2001-02-20 2004-10-15 Rheogene Holdings Inc Nuevo sistema de expresion genetica inducible a base de receptor de ecdisona/receptor x retinoide de invertebrado.
US8715959B2 (en) 2001-02-20 2014-05-06 Intrexon Corporation Substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
ES2390070T3 (es) 2001-02-20 2012-11-06 Intrexon Corporation Nuevos receptores mutantes de sustitución y su uso en un sistema de expresión génica inducible basado en receptores nucleares
JP4955905B2 (ja) 2001-02-20 2012-06-20 イントレキソン コーポレーション キメラレチノイドｘ受容体および新規エクジソン受容体−ベースの誘導性遺伝子発現システムにおけるそれらの使用
CA2441476A1 (en) 2001-03-02 2002-09-12 The Rockefeller University Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
AU2002329176A1 (en) 2001-05-25 2002-12-23 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
WO2002100435A1 (en) * 2001-06-11 2002-12-19 Centre Hospitalier Universitaire De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
FR2829136B1 (fr) 2001-08-29 2006-11-17 Aventis Pharma Sa Derives lipidiques d'aminoglycosides
US7919269B2 (en) 2001-09-26 2011-04-05 Intrexon Corporation Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
WO2003027289A1 (en) 2001-09-26 2003-04-03 Rheo Gene Holdings, Inc. Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
US20040023910A1 (en) * 2001-09-28 2004-02-05 Zhiming Zhang Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
PT1479985T (pt) 2002-01-17 2017-08-03 Alfa Laval Corp Ab Evaporador submerso compreendendo um permutador de calor de placas e um compartimento cilíndrico onde está disposto o permutador de calor de placas
US7037520B2 (en) * 2002-03-22 2006-05-02 Baylor College Of Medicine Reversible masking of liposomal complexes for targeted delivery
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
JP4791730B2 (ja) * 2002-09-27 2011-10-12 パウダージェクト リサーチ リミテッド 核酸コーティング粒子
CA2513072A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
WO2005010157A2 (en) * 2003-07-15 2005-02-03 Cedars-Sinai Medical Center Use of pleiotrophin in the diagnosis, treatment and prevention of disease
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
AU2004297533B2 (en) 2003-10-24 2010-04-29 Gencia Corporation Methods and compositions for delivering polynucleotides
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US7432057B2 (en) 2004-01-30 2008-10-07 Michigan State University Genetic test for PSE-susceptible turkeys
ATE483981T1 (de) 2004-04-20 2010-10-15 Galapagos Nv Verfahren, zusammensetzungen und verbindungstests zur hemmung der amyloid-beta-proteinproduktion
EP2214018B1 (de) 2004-04-27 2013-06-26 Galapagos N.V. Verfahren, Agentien und Screening-tests für Verbindungen zur Induktion der Differenzierung undifferenzierter Säugerzellen zu Osteoblasten
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
MXPA06014577A (es) 2004-06-14 2007-03-23 Galapagos Nv Metodos para la identificacion y compuestos utiles para el tratamiento de enfermedades degenerativas e inflamatorias.
PL2031063T3 (pl) 2004-06-18 2014-04-30 Univ Duke Modulatory receptorów węchowych
ES2427046T3 (es) 2004-06-21 2013-10-28 Galapagos N.V. Métodos y medios para el tratamiento de la osteoartritis
US7604798B2 (en) 2004-07-15 2009-10-20 Northwestern University Methods and compositions for importing nucleic acids into cell nuclei
AU2005274948B2 (en) 2004-07-16 2011-09-22 Genvec, Inc. Vaccines against aids comprising CMV/R-nucleic acid constructs
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
US9034650B2 (en) 2005-02-02 2015-05-19 Intrexon Corporation Site-specific serine recombinases and methods of their use
CA2611944A1 (en) * 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
US8088382B2 (en) 2005-07-05 2012-01-03 Cornell Research Foundation, Inc. Methods of inhibiting transendothelial migration of neutrophils and monocytes with anti-CD99L2 antibodies
US7666584B2 (en) 2005-09-01 2010-02-23 Philadelphia Health & Education Coporation Identification of a pin specific gene and protein (PIN-1) useful as a diagnostic treatment for prostate cancer
KR101573928B1 (ko) * 2006-05-15 2015-12-03 조지타운 유니버시티 치료제 또는 진단제의 전신 투여를 위한 항체- 또는 항체 단편-표적화 면역리포좀 제제 및 그의 용도
KR100857389B1 (ko) 2006-06-30 2008-09-11 (주)아모레퍼시픽 Ａｐ-ｇｒｒ 펩티드 또는 ａｐ-ｇｒｒ 펩티드를 포함하는펩티드사슬 및 이를 포함하는 약물전달담체
AU2007276793B2 (en) 2006-07-28 2014-01-16 Sanofi Composition and method for treatment of tumors
WO2008040792A2 (en) 2006-10-04 2008-04-10 Centre National De La Recherche Scientifique (Cnrs) Compositions comprising a sirna and lipidic 4,5-disubstituted 2-deoxystreptamine ring aminoglycoside derivatives and uses thereof
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2155910A4 (de) 2007-05-08 2010-06-02 Univ Duke Zusammensetzungen und verfahren zur charakterisierung und regulierung der geruchswahrnehmung
US8076517B2 (en) 2007-05-29 2011-12-13 Intrexon Corporation Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US8637257B2 (en) 2007-06-20 2014-01-28 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
US20090069266A1 (en) 2007-06-27 2009-03-12 Northwestern University Methods and compositions for nucleic acid transfer into cells
SG182994A1 (en) * 2007-07-09 2012-08-30 Univ Georgetown Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
EP2185730A4 (de) 2007-08-23 2010-10-27 Intrexon Corp Verfahren und zusammensetzungen zur krankheitsdiagnose
WO2009036368A2 (en) * 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
EP2183355B1 (de) * 2007-09-17 2016-01-27 Rohm and Haas Company Zusammensetzungen und verfahren zur modifizierung physiologischer reaktionen in pflanzen
AU2008307643B9 (en) 2007-09-28 2014-04-17 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
EP2042193A1 (de) 2007-09-28 2009-04-01 Biomay AG RNA-Impfstoffe
AU2008311292B9 (en) 2007-10-08 2014-10-09 Intrexon Corporation Engineered dendritic cells and uses for the treatment of cancer
FR2928373B1 (fr) 2008-03-05 2010-12-31 Centre Nat Rech Scient Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
US8765376B2 (en) 2008-09-11 2014-07-01 Galapagos Nv Methods for identifying and compounds useful for increasing the functional activity and cell surface expression of CF-associated mutant cystic fibrosis transmembrane conductance regulator
ES2648231T3 (es) 2008-11-05 2017-12-29 Wyeth Llc Composición inmunogénica de múltiples componentes para la prevención de la enfermedad por estreptococos beta hemolíticos (EBH)
EP2365962B1 (de) 2008-11-07 2017-07-05 Massachusetts Institute of Technology Aminoalkohollipidoide und anwendungen davon
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
EP2398481A2 (de) 2009-02-19 2011-12-28 Galapagos N.V. Verfahren zur identifizierung und verbindungen zur diagnose und behandlung von mit entzündung einhergehenden krankheiten
EP2398479A2 (de) 2009-02-19 2011-12-28 Galapagos N.V. Verfahren zur identifizierung und verbindungen zur diagnose und behandlung von mit entzündung einhergehenden krankheiten
WO2010094732A1 (en) 2009-02-19 2010-08-26 Biofocus Dpi B.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
WO2010115825A2 (en) 2009-03-31 2010-10-14 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
WO2010112569A1 (en) 2009-03-31 2010-10-07 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
JP2012522977A (ja) 2009-04-01 2012-09-27 ガラパゴス・ナムローゼ・フェンノートシャップ 変形性関節症の治療のための方法及び手段
US8362218B2 (en) 2009-04-17 2013-01-29 New York University School Of Medicine Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof
WO2011015572A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015573A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
EP2547368A4 (de) 2010-03-19 2014-08-06 Univ South Alabama Verfahren und zusammensetzungen zur krebsbehandlung
WO2011119773A1 (en) 2010-03-23 2011-09-29 Roeth Jeremiah F Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
CN103189071A (zh) 2010-08-23 2013-07-03 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
EP3056212B1 (de) 2010-09-10 2019-04-03 Wyeth LLC Non-lipidierten varianten von neisseria meningitidis orf2086 antigene
CN103476928B (zh) 2010-12-09 2017-03-29 巴斯德研究所 用于获得高产量重组蛋白表达的基于mgmt的方法
EP2492279A1 (de) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Schnelles immunogenes Auswahlverfahren mittels Lentivirenanzeige
EP3450568A3 (de) 2011-03-04 2019-04-24 Intrexon Corporation Vektoren für bedingte proteinexpression
EP2691443B1 (de) 2011-03-28 2021-02-17 Massachusetts Institute of Technology Konjugierte lipomers und ihre verwendung
WO2012135696A2 (en) 2011-04-01 2012-10-04 University Of South Alabama Methods and compositions for the diagnosis, classification, and treatment of cancer
EP2546358A1 (de) 2011-07-15 2013-01-16 Laboratorios Del. Dr. Esteve, S.A. Verfahren und Reagenzien zur effizienten Steuerung des HIV-Fortschritts
US9127040B2 (en) 2011-09-20 2015-09-08 The University Of North Carolina At Chapel Hill Regulation of sodium channels by PLUNC proteins
WO2013053765A1 (en) 2011-10-11 2013-04-18 Proyecto De Biomedicina Cima, S.L. A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma
PE20150041A1 (es) 2011-10-27 2015-01-28 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
EP2788478B1 (de) 2011-12-09 2017-08-23 Institut Pasteur Multiplex-immunoscreening-test
WO2013103401A1 (en) 2012-01-06 2013-07-11 University Of South Alabama Methods and compositions for the treatment of cancer
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX2018011291A (es) 2012-03-09 2023-01-31 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
EP2698377A1 (de) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Verbessertes schnelles Immunogene Auswahlverfahren für HIV gp120 Varianten
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
US20160054304A1 (en) 2013-03-14 2016-02-25 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases
WO2014139885A2 (en) 2013-03-14 2014-09-18 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition
WO2014139884A2 (en) 2013-03-14 2014-09-18 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrosis
CN105283439B (zh) 2013-03-15 2018-02-02 英特瑞克斯顿股份有限公司 含硼的二酰基肼类化合物
US20160130585A1 (en) 2013-05-28 2016-05-12 The Johns Hopkins University Aptamers for the treatment of sickle cell disease
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
KR101605421B1 (ko) 2014-03-05 2016-03-23 국립암센터 B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
AU2015317862A1 (en) 2014-09-17 2017-04-06 Intrexon Corporation Boron-containing diacylhydrazine compounds
CN107531774B (zh) 2015-02-06 2021-12-14 北卡罗来纳大学查珀尔希尔分校 优化的人类凝血因子viii基因表达盒及其用途
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
TW201710503A (zh) 2015-06-12 2017-03-16 長庚醫療財團法人林口長庚紀念醫院 新穎多核苷酸、載體、醫藥組成物以及其用途
EP3310764B1 (de) 2015-06-19 2023-04-19 Massachusetts Institute of Technology Alkenyl substituierte 2,5-piperazindione und ihre verwendung in zusammensetzungen zur verabreichung eines mittels an eine person oder in eine zelle
WO2017053170A1 (en) 2015-09-24 2017-03-30 The University Of North Carolina At Chapel Hill Methods and compositions for reducing metastases
WO2017062953A1 (en) 2015-10-10 2017-04-13 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
AU2017222450A1 (en) 2016-02-22 2018-09-27 The University Of North Carolina At Chapel Hill Peptide inhibitors of calcium channels
MX2019005235A (es) 2016-11-09 2019-12-05 Intrexon Corp Constructos de expresion de frataxina.
JP6661797B2 (ja) 2016-11-22 2020-03-11 株式会社東芝 核酸凝縮ペプチド、核酸凝縮ペプチドセット、核酸送達キャリア、核酸送達方法、細胞作製方法、細胞検出方法及びキット
SG10202111092UA (en) 2017-01-31 2021-11-29 Pfizer Neisseria meningitidis compositions and methods thereof
US20200393446A1 (en) 2017-12-08 2020-12-17 Centre National De La Recherche Scientifique (Cnrs) Bioluminescent screening test for detecting cell cytolysis
EP3539975A1 (de) 2018-03-15 2019-09-18 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Mikropeptide und verwendungen davon
WO2020032784A1 (ko) 2018-08-10 2020-02-13 주식회사 유틸렉스 Hla-dr에 결합하는 키메라 항원 수용체 및 car-t 세포
US20220175781A1 (en) 2019-03-08 2022-06-09 Obsidian Therapeutics, Inc. Cd40l compositions and methods for tunable regulation
US20210069242A1 (en) 2019-04-18 2021-03-11 Dmitry Dmitrievich Genkin Reprogramming of polymorphonuclear leukocytes
AU2021205416A1 (en) 2020-01-08 2022-08-25 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of transcription
EP3885440A1 (de) 2020-03-26 2021-09-29 Splicebio, S.L. Spaltinteine und deren verwendungen
WO2023242436A1 (en) 2022-06-17 2023-12-21 Danmarks Tekniske Universitet Allergy vaccines based on consensus allergens

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486479T2 (de) 1983-10-20 2001-09-20 The Research Foundation Of State University Of New York, Albany Regulierung der Genexpression durch Translationshemmung unter Verwendung von mRNA hindernder Komplementär-RNA
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
FR2602790B1 (fr) 1986-08-13 1990-06-01 Transgene Sa Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante
AU632993B2 (en) 1987-12-15 1993-01-21 Gene Shears Pty. Limited Ribozymes
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
ES2200016T3 (es) 1989-03-21 2004-03-01 Vical Incorporated Expresion de secuencias polinucleotidicas exogenas en un vertebrado.
FR2646161B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5286634A (en) 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
DE59106279D1 (de) * 1990-05-18 1995-09-21 Genentech Inc Neue protein-polykation-konjugate.
FR2681786A1 (fr) 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
PT636028E (pt) * 1992-04-03 2004-07-30 Univ California Sistema de fornecimento de polinucleotidos auto-organizado
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
FR2704234B1 (fr) 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
SG54115A1 (en) 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
FR2704556B1 (fr) 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations

Also Published As

Publication number Publication date
KR19980702200A (ko) 1998-07-15
MX9706016A (es) 1997-11-29
DE69635609T2 (de) 2006-09-14
US5945400A (en) 1999-08-31
FR2730637B1 (fr) 1997-03-28
US6200956B1 (en) 2001-03-13
IL117144A0 (en) 1996-06-18
FI973363A0 (fi) 1997-08-15
DE69635609D1 (de) 2006-01-26
AU4835396A (en) 1996-09-04
FI973363A (fi) 1997-08-15
FR2730637A1 (fr) 1996-08-23
HU223263B1 (hu) 2004-04-28
SK111897A3 (en) 1998-02-04
CZ293269B6 (cs) 2004-03-17
BR9607383A (pt) 1997-11-25
WO1996025508A1 (fr) 1996-08-22
EP0809705A1 (de) 1997-12-03
NO973745D0 (no) 1997-08-14
EP0809705B1 (de) 2005-12-21
CZ259297A3 (en) 1997-11-12
AU706643B2 (en) 1999-06-17
CA2211162A1 (fr) 1996-08-22
HUP9801207A3 (en) 2000-12-28
HUP9801207A2 (hu) 1998-08-28
NO973745L (no) 1997-08-14
JPH11500431A (ja) 1999-01-12
ZA961255B (en) 1996-08-27
SK281543B6 (sk) 2001-04-09

Similar Documents

Publication Publication Date Title
ATE313642T1 (de) Nukleinsäure enthaltende zusammensetzung, herstellung und verwendung
ATE312190T1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
DE69333731D1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
BR0010952A (pt) Material de revestimento com uma mistura de ácidos silìcicos e uréia e/ou derivados de uréia
NO905608L (no) Fremgangsmaate for fremstilling av a-nor-steroid-3-karboksylsyrederivater.
DE69828045D1 (de) Verbindungen, ihre herstellung und ihre verwendung für den transfer von nucleinsäuren in zellen
BR9803727A (pt) Tintas biostáveis de base em água e processo para suas preparações.
DE69020979D1 (de) Neue Arginin-Deiminase, Verfahren zu ihrer Herstellung und ein Antikrebsmittel, das dieses Enzym als wirksamen Bestandteil enthält.
IL137247A0 (en) Transfecting compositions sensitive to reducing conditions, pharmaceutical compositions containing them, and their applications
HUP0004577A1 (hu) Kationos nukleinsav transzfekciós ágensek új csoportja
DE69734596D1 (de) "smoothened" proteine aus wirbeltieren
FI951759A0 (fi) Menetelmä 2,2-difluoriketeenisilyyli-O,S-asetaalien ja alfa, alfa-difluori-beta-silyylioksi-1,3-dioksolaani-4-propaanihapon O,S-estereiden valmistamiseksi
DE69801811D1 (de) Alkykendiamin di- oder tri-essigsäurederivate, verfahren zu ihrer herstellung und ihre verwendung in kosmetischen zusammensetzungen
DE69616085D1 (de) Aminonitril-zwischenprodukte zur herstellung von 2-hydroxyethyliminodiessigsäure
DE60031315D1 (de) Verfahren zur Herstellung von Derivaten von i(1,5-Diaryl)pyrazol-3-ylöpropansäure
ES8506029A1 (es) Un procedimiento para la preparacion de un compuesto
BR9813102A (pt) Derivados de ácido metilenobisfosfÈnico novos
ATE183502T1 (de) Octahydro-2-naphthalincarbonsäure-derivate, ihre herstellung und verwendung
DE59003446D1 (de) 13-Brom und 13, 14-Dibrom-Ergoline, ihre Herstellung und Verwendung in Arzneimitteln.
ATE46692T1 (de) (6,11-dihydro-11-oxodibenz(b,e>oxepinyl)pentaans|uren und derivate, verfahren und zwischenprodukte zu deren herstellung und deren verwendung als arzneimittel.
DE69109953D1 (de) Alfa-fluorocarbonsäurederivate als Zwischenprodukte zur Herstellung von Fungiziden.
BR9812869A (pt) Processo para a preparação de benzofuranonas eventualmente substituìdas
MX9801920A (es) Composicion farmaceutica util para la transfeccion de acidos nucleicos y sus usos.
RU94046405A (ru) Птг-соединения и содержащий их фармацевтический состав, способ получения желаемых полипептидов, нуклеотидная последовательность, бактериальный вектор экспрессии, бактериальные хозяйские клетки и составной белок
UA10420A (uk) Аhтиалкогольhий та аhтиhаркотичhий засіб

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties